- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
WeedMD Exports Cannabis Genetics to Israeli Partner
WeedMD announced it exported cannabis genetics to a private medical cannabis producer in Israel.
WeedMD (TSXV:WMD) announced it exported cannabis genetics to a private medical cannabis producer in Israel.
As quoted in the press release:
WeedMD, a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce it has exported its cannabis genetics to Israel’s Pharmocann, a privately-held pharma-agricultural medical cannabis producer working under the authorization of Israel’s Ministry of Health and widely recognized as a pioneer in the worldwide medical cannabis industry.
“We are delighted that Pharmocann, one of the world leaders and advocates in the medical cannabis community, has selected WeedMD’s genetics to strengthen its robust genetics library. Israel has been researching and advancing medical cannabis for well over 50 years, and Pharmocann has been providing high-quality products to medical patients for over a decade,” said Keith Merker, CEO of WeedMD. “Widely lauded for its breakthrough developments in cannabis treatments, we welcome the Pharmocann team to WeedMD’s expanding list of international genetics customers.”
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.